dexamfetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anorexics 841 51-64-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dextroamphetamine
  • S-Amphetamine
  • D-Amphetamine
  • dexadrine
  • dexamfetamine
  • dextroamphetamine sulfate
  • dextroamphetamine saccharate
  • dextroamphetamine adipate
  • dextroamphetamine resin complex
The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
  • Molecular weight: 135.21
  • Formula: C9H13N
  • CLOGP: 1.74
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -1.89
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.40 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 40
kinase-selectivity-class AKT2,AKT3,AXL,FLT3,GRK2,PDK4,PRKCD,SIK2 8
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Sept. 9, 1955 FDA UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site erythema 129.00 15.36 40 10313 5168 90612926
Product administration interrupted 125.81 15.36 49 10304 12443 90605651
Application site pain 103.36 15.36 33 10320 4687 90613407
Application site irritation 102.64 15.36 27 10326 1934 90616160
Anxiety 91.25 15.36 142 10211 309630 90308464
Application site swelling 81.00 15.36 18 10335 629 90617465
Suicidal ideation 78.36 15.36 66 10287 73789 90544305
Application site pruritus 78.03 15.36 26 10327 4221 90613873
Coronary artery dissection 68.97 15.36 17 10336 937 90617157
Depression 64.84 15.36 120 10233 300481 90317613
Feeling abnormal 59.71 15.36 84 10269 167151 90450943
Pre-existing condition improved 58.58 15.36 26 10327 9143 90608951
Migraine 48.75 15.36 82 10271 190310 90427784
Cataplexy 47.64 15.36 14 10339 1506 90616588
Surgery 39.33 15.36 36 10317 44851 90573243
Product dose omission issue 39.10 15.36 96 10257 291591 90326503
Somnolence 38.34 15.36 78 10275 209006 90409088
Dermatitis atopic 35.77 15.36 26 10327 23446 90594648
Sleep apnoea syndrome 34.95 15.36 29 10324 31718 90586376
Product substitution issue 34.60 15.36 23 10330 17985 90600109
Suspected product quality issue 32.76 15.36 8 10345 424 90617670
Disturbance in attention 32.27 15.36 33 10320 47076 90571018
Infusion related reaction 29.27 15.36 6 10347 416774 90201320
Application site rash 28.75 15.36 11 10342 2658 90615436
Therapeutic response unexpected 28.37 15.36 22 10331 21858 90596236
Hepatic enzyme increased 27.95 15.36 4 10349 360732 90257362
Overdose 27.91 15.36 58 10295 157651 90460443
Intentional self-injury 26.62 15.36 24 10329 29310 90588784
Serotonin syndrome 24.97 15.36 26 10327 37861 90580233
Dissociation 24.57 15.36 13 10340 6702 90611392
Glossodynia 23.94 15.36 4 10349 321775 90296319
Neuroleptic malignant syndrome 23.64 15.36 17 10336 15079 90603015
Application site reaction 23.21 15.36 7 10346 823 90617271
Irritability 22.66 15.36 24 10329 35638 90582456
Snoring 21.85 15.36 11 10342 5115 90612979
Mydriasis 21.46 15.36 16 10337 14996 90603098
Mental disorder 20.98 15.36 22 10331 32296 90585798
Panic attack 20.89 15.36 20 10333 26345 90591749
Piloerection 20.47 15.36 6 10347 640 90617454
Systemic lupus erythematosus 20.26 15.36 8 10345 361888 90256206
Restless legs syndrome 19.64 15.36 18 10335 22452 90595642
Colitis ischaemic 19.55 15.36 14 10339 12332 90605762
Rhabdomyolysis 18.64 15.36 26 10327 51230 90566864
Bipolar disorder 18.54 15.36 12 10341 8973 90609121
Nervousness 18.31 15.36 21 10332 34035 90584059
Application site discolouration 18.26 15.36 6 10347 932 90617162
Stress 18.13 15.36 33 10320 81362 90536732
Attention deficit hyperactivity disorder 17.90 15.36 9 10344 4175 90613919
Muscle rigidity 17.71 15.36 14 10339 14295 90603799
Intentional overdose 17.16 15.36 35 10318 93799 90524295
Maternal exposure during pregnancy 17.04 15.36 10 10343 360053 90258041
Sedation 16.87 15.36 24 10329 48147 90569947
Hypothermia 16.67 15.36 14 10339 15561 90602533
Contraindicated product administered 16.45 15.36 8 10345 320131 90297963
Multiple sclerosis 16.39 15.36 18 10335 27822 90590272
Weight decreased 16.30 15.36 86 10267 379824 90238270
Post-traumatic stress disorder 16.30 15.36 10 10343 6818 90611276
Agitation 15.96 15.36 28 10325 67070 90551024
Drug ineffective 15.72 15.36 233 10120 1384065 89234029
Swelling 15.52 15.36 15 10338 419043 90199051
Mood altered 15.50 15.36 14 10339 17130 90600964
Stomatitis 15.49 15.36 6 10347 274692 90343402
Application site warmth 15.45 15.36 4 10349 269 90617825
Joint swelling 15.41 15.36 21 10332 503279 90114815

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oppositional defiant disorder 121.48 21.99 25 5319 547 42615444
Decreased eye contact 117.78 21.99 24 5320 499 42615492
Aggression 96.04 21.99 63 5281 44100 42571891
Bruxism 92.90 21.99 26 5318 2143 42613848
Coordination abnormal 86.69 21.99 34 5310 8016 42607975
Homicidal ideation 82.10 21.99 25 5319 2769 42613222
Anxiety 80.30 21.99 86 5258 118474 42497517
Crying 79.55 21.99 30 5314 6364 42609627
Suicidal ideation 79.50 21.99 58 5286 48103 42567888
Poor quality sleep 74.78 21.99 32 5312 9408 42606583
Product substitution issue 72.43 21.99 33 5311 11257 42604734
Affect lability 69.13 21.99 24 5320 4020 42611971
Choreoathetosis 64.87 21.99 17 5327 1092 42614899
Trismus 60.66 21.99 20 5324 2864 42613127
Mood altered 58.44 21.99 28 5316 10690 42605301
Irritability 58.37 21.99 39 5305 28089 42587902
Depression 55.49 21.99 69 5275 111294 42504697
Insomnia 55.33 21.99 71 5273 118182 42497809
Psychomotor hyperactivity 51.88 21.99 26 5318 10932 42605059
Application site pain 48.37 21.99 16 5328 2313 42613678
Application site erythema 46.85 21.99 16 5328 2550 42613441
Extrasystoles 46.09 21.99 18 5326 4191 42611800
Supraventricular extrasystoles 43.40 21.99 17 5327 3989 42612002
Speech disorder 43.38 21.99 33 5311 29088 42586903
Product administration interrupted 43.21 21.99 18 5326 4948 42611043
Streptococcal infection 42.74 21.99 19 5325 6113 42609878
Hyperkinesia 41.92 21.99 14 5330 2084 42613907
Application site irritation 41.63 21.99 11 5333 729 42615262
Intentional overdose 41.38 21.99 41 5303 51415 42564576
Hypertensive emergency 39.79 21.99 12 5332 1285 42614706
Dyskinesia 38.32 21.99 29 5315 25361 42590630
Depressed mood 38.17 21.99 28 5316 23356 42592635
Posterior reversible encephalopathy syndrome 37.21 21.99 22 5322 12799 42603192
Sleep apnoea syndrome 35.56 21.99 26 5318 21582 42594409
Dystonia 34.66 21.99 21 5323 12769 42603222
Tic 32.63 21.99 12 5332 2371 42613620
Drug tolerance 32.28 21.99 13 5331 3277 42612714
Anger 31.78 21.99 20 5324 12998 42602993
Therapeutic response unexpected 31.65 21.99 19 5325 11362 42604629
Educational problem 29.71 21.99 8 5336 570 42615421
Application site rash 29.52 21.99 9 5335 1000 42614991
Neutrophil hypersegmented morphology present 27.89 21.99 4 5340 7 42615984
Vision blurred 27.86 21.99 34 5310 53665 42562326
Product complaint 27.75 21.99 14 5330 5963 42610028
Sleep disorder 27.50 21.99 32 5312 48063 42567928
Pre-existing condition improved 26.65 21.99 11 5333 2952 42613039
Nervousness 26.23 21.99 18 5326 13514 42602477
Pneumonia 24.81 21.99 11 5333 422138 42193853
Coronary ostial stenosis 24.39 21.99 5 5339 107 42615884
Sexual dysfunction 23.33 21.99 13 5331 6762 42609229
Cardio-respiratory arrest 22.47 21.99 32 5312 58604 42557387
Intentional self-injury 22.13 21.99 17 5327 15185 42600806
Suicide attempt 22.00 21.99 28 5316 46072 42569919

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oppositional defiant disorder 128.25 15.31 25 11629 493 110577152
Anxiety 124.68 15.31 167 11487 344911 110232734
Product administration interrupted 112.52 15.31 43 11611 11249 110566396
Suicidal ideation 110.07 15.31 86 11568 93851 110483794
Decreased eye contact 108.53 15.31 24 11630 891 110576754
Application site erythema 108.48 15.31 35 11619 5575 110572070
Application site irritation 95.43 15.31 25 11629 1912 110575733
Bruxism 91.86 15.31 30 11624 4964 110572681
Aggression 89.05 15.31 63 11591 59147 110518498
Homicidal ideation 84.13 15.31 26 11628 3601 110574044
Product substitution issue 80.19 15.31 42 11612 23019 110554626
Intentional overdose 77.33 15.31 82 11572 132419 110445226
Application site pain 73.50 15.31 26 11628 5473 110572172
Application site swelling 71.56 15.31 17 11637 870 110576775
Coronary artery dissection 70.69 15.31 18 11636 1230 110576415
Depression 68.38 15.31 121 11533 317214 110260431
Crying 62.60 15.31 37 11617 25591 110552054
Serotonin syndrome 58.34 15.31 49 11605 59104 110518541
Choreoathetosis 56.08 15.31 16 11638 1682 110575963
Coordination abnormal 52.82 15.31 33 11621 25195 110552450
Feeling abnormal 52.59 15.31 79 11575 180632 110397013
Mood altered 52.57 15.31 31 11623 21344 110556301
Irritability 52.16 15.31 42 11612 47767 110529878
Poor quality sleep 52.01 15.31 34 11620 28043 110549602
Psychomotor hyperactivity 51.43 15.31 30 11624 20247 110557398
Overdose 51.42 15.31 90 11564 233704 110343941
Trismus 47.90 15.31 20 11634 6576 110571069
Application site pruritus 45.63 15.31 17 11637 4143 110573502
Intentional self-injury 45.39 15.31 35 11619 37394 110540251
Affect lability 43.15 15.31 26 11628 18611 110559034
Application site rash 42.17 15.31 14 11640 2436 110575209
Dyskinesia 41.46 15.31 38 11616 51408 110526237
Extrasystoles 40.34 15.31 19 11635 8299 110569346
Hyperkinesia 38.58 15.31 14 11640 3170 110574475
Supraventricular extrasystoles 37.80 15.31 18 11636 8055 110569590
Dystonia 37.72 15.31 27 11627 25778 110551867
Speech disorder 37.48 15.31 39 11615 61530 110516115
Streptococcal infection 35.49 15.31 19 11635 10871 110566774
Mydriasis 34.28 15.31 24 11630 22133 110555512
Suicide attempt 34.13 15.31 48 11606 103346 110474299
Disturbance in attention 33.73 15.31 37 11617 61958 110515687
Tic 33.71 15.31 13 11641 3480 110574165
Nervousness 33.22 15.31 29 11625 36822 110540823
Insomnia 33 15.31 98 11556 360492 110217153
Depressed mood 32.58 15.31 36 11618 60773 110516872
Educational problem 31.51 15.31 8 11646 540 110577105
Hypertensive emergency 30.67 15.31 12 11642 3339 110574306
Anger 30.37 15.31 21 11633 18986 110558659
Cataplexy 29.75 15.31 9 11645 1160 110576485
Dissociation 28.82 15.31 16 11638 9826 110567819
Hyperhidrosis 28.78 15.31 62 11592 187236 110390409
Cardio-respiratory arrest 28.62 15.31 47 11607 115789 110461856
Abnormal behaviour 27.94 15.31 27 11627 39012 110538633
Product dose omission issue 27.13 15.31 85 11569 321697 110255948
Anaemia 26.91 15.31 12 11642 547074 110030571
Surgery 26.66 15.31 27 11627 41256 110536389
Neutropenia 26.37 15.31 4 11650 374616 110203029
Toxicity to various agents 26.12 15.31 110 11544 480445 110097200
Pre-existing condition improved 25.91 15.31 13 11641 6513 110571132
Pneumonia 25.57 15.31 33 11621 876681 109700964
Posterior reversible encephalopathy syndrome 25.33 15.31 24 11630 33837 110543808
Completed suicide 25.19 15.31 69 11585 242312 110335333
Neutrophil hypersegmented morphology present 24.08 15.31 4 11650 30 110577615
Shoulder operation 23.53 15.31 10 11644 3435 110574210
Drug tolerance 23.43 15.31 17 11637 16568 110561077
Agitation 22.87 15.31 42 11612 113009 110464636
Dermatitis atopic 22.82 15.31 20 11634 25521 110552124
Panic attack 22.58 15.31 21 11633 28919 110548726
Sedation 22.47 15.31 32 11622 69651 110507994
Ileal ulcer 22.05 15.31 8 11646 1809 110575836
Therapeutic response unexpected 21.96 15.31 19 11635 23824 110553821
Sleep apnoea syndrome 21.76 15.31 24 11630 40423 110537222
Ventricular fibrillation 21.34 15.31 24 11630 41289 110536356
Plagiocephaly 21.25 15.31 4 11650 65 110577580
Drug withdrawal syndrome 21.20 15.31 23 11631 38031 110539614
Attention deficit hyperactivity disorder 20.98 15.31 10 11644 4481 110573164
General physical health deterioration 19.87 15.31 10 11644 425285 110152360
Somnolence 19.29 15.31 72 11582 297377 110280268
Piloerection 19.19 15.31 6 11648 863 110576782
Paranoia 18.95 15.31 17 11637 22357 110555288
Psychiatric decompensation 18.62 15.31 10 11644 5755 110571890
Thrombocytopenia 18.19 15.31 7 11647 348878 110228767
Colitis ischaemic 18.11 15.31 15 11639 17735 110559910
Application site discolouration 18.08 15.31 6 11648 1043 110576602
Vision blurred 17.88 15.31 41 11613 128981 110448664
Joint swelling 17.10 15.31 13 11641 442832 110134813
Gross motor delay 16.91 15.31 4 11650 201 110577444
Death 16.79 15.31 30 11624 698839 109878806
Pyrexia 16.30 15.31 45 11609 898220 109679425
Infusion related reaction 16.30 15.31 10 11644 381152 110196493
Substance use 16.21 15.31 7 11647 2499 110575146
Fatigue 16.07 15.31 197 11457 1215761 109361884
Muscle rigidity 16.04 15.31 16 11638 24015 110553630
Restless legs syndrome 15.71 15.31 16 11638 24610 110553035
Acute kidney injury 15.51 15.31 27 11627 635403 109942242
Febrile neutropenia 15.48 15.31 7 11647 316760 110260885

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06BA02 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
FDA PE N0000175729 Central Nervous System Stimulation
FDA EPC N0000175739 Central Nervous System Stimulant
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:35640 adrenergic uptake inhibitors
CHEBI has role CHEBI:37962 adrenergic agents
CHEBI has role CHEBI:48560 dopaminergic agents
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:51039 dopamine reuptake inhibitor

Related Drugs by ATC class:

N06BA Centrally acting sympathomimetics 14 drugs
amfetaminearmodafinilatomoxetinedexmethylphenidatefencamfaminfenetyllinefenozolonelisdexamfetaminemethamphetaminemethylphenidatemodafinilpemoline show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Narcolepsy indication 60380001 DOID:8986
Attention deficit hyperactivity disorder indication 406506008
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Dependent drug abuse contraindication 6525002
Bipolar disorder contraindication 13746004 DOID:3312
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.89 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
12.5MG;12.5MG;12.5MG;12.5MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG;3.125MG;3.125MG;3.125MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG;6.25MG;6.25MG;6.25MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG;9.375MG;9.375MG;9.375MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
13.5MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL 9456993 Oct. 24, 2033 A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
18MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL 9456993 Oct. 24, 2033 A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
4.5MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL 9456993 Oct. 24, 2033 A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
9MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL 9456993 Oct. 24, 2033 A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter RELEASING AGENT Ki 6.68 WOMBAT-PK CHEMBL
Synaptic vesicular amine transporter Transporter INHIBITOR CHEMBL CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7 IUPHAR CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.18 PDSP
Alpha-1A adrenergic receptor GPCR WOMBAT-PK
Cocaine- and amphetamine-regulated transcript protein Transcription factor WOMBAT-PK
Amine oxidase [flavin-containing] A Enzyme Ki 4.84 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 6.87 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.24 CHEMBL
Sodium-dependent dopamine transporter Transporter IC50 5.31 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 4.91 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 6 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 7.25 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 8.70 CHEMBL
Sodium-dependent serotonin transporter Transporter EC50 5.75 CHEMBL
Serotonin (5-HT) receptor GPCR Kd 5.35 CHEMBL

External reference:

IDSource
4019978 VUID
N0000148062 NUI
D02078 KEGG_DRUG
51-63-8 SECONDARY_CAS_RN
350708-40-6 SECONDARY_CAS_RN
221088 RXNORM
4018004 VANDF
4018005 VANDF
4018835 VANDF
4019978 VANDF
C0011812 UMLSCUI
1WE PDB_CHEM_ID
CHEMBL612 ChEMBL_ID
CHEMBL3544971 ChEMBL_ID
CHEMBL3989844 ChEMBL_ID
CHEMBL1200782 ChEMBL_ID
DB01576 DRUGBANK_ID
2147 IUPHAR_LIGAND_ID
64770-52-1 SECONDARY_CAS_RN
5826 PUBCHEM_CID
1604 MMSL
40549 MMSL
4563 MMSL
4564 MMSL
d00804 MMSL
001793 NDDF
001795 NDDF
006720 NDDF
387022005 SNOMEDCT_US
387278002 SNOMEDCT_US
45207006 SNOMEDCT_US
50868004 SNOMEDCT_US
D003913 MESH_DESCRIPTOR_UI
CHEBI:4469 CHEBI
1430 INN_ID
TZ47U051FI UNII
TZ47U051FI INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1328 CAPSULE, EXTENDED RELEASE 1.25 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1328 CAPSULE, EXTENDED RELEASE 1.25 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1329 CAPSULE, EXTENDED RELEASE 2.50 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1329 CAPSULE, EXTENDED RELEASE 2.50 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1330 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1330 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1331 CAPSULE, EXTENDED RELEASE 5 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1331 CAPSULE, EXTENDED RELEASE 5 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1332 CAPSULE, EXTENDED RELEASE 6.25 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1332 CAPSULE, EXTENDED RELEASE 6.25 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1333 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1333 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1490 CAPSULE 6.25 mg ORAL ANDA 29 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1490 CAPSULE 6.25 mg ORAL ANDA 29 sections